MY202167A - Sulfone pyridine alkyl amide-substituted heteroaryl compounds - Google Patents

Sulfone pyridine alkyl amide-substituted heteroaryl compounds

Info

Publication number
MY202167A
MY202167A MYPI2020002150A MYPI2020002150A MY202167A MY 202167 A MY202167 A MY 202167A MY PI2020002150 A MYPI2020002150 A MY PI2020002150A MY PI2020002150 A MYPI2020002150 A MY PI2020002150A MY 202167 A MY202167 A MY 202167A
Authority
MY
Malaysia
Prior art keywords
substituted heteroaryl
alkyl amide
heteroaryl compounds
pyridine alkyl
sulfone
Prior art date
Application number
MYPI2020002150A
Other languages
English (en)
Inventor
Chunjian Liu
Michael G Yang
Zili Xiao
Ling Chen
Ryan M Moslin
John S Tokarski
David S Weinstein
Stephen T Wrobleski
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MY202167A publication Critical patent/MY202167A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2020002150A 2017-11-21 2018-11-19 Sulfone pyridine alkyl amide-substituted heteroaryl compounds MY202167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589165P 2017-11-21 2017-11-21
PCT/US2018/061726 WO2019103952A1 (en) 2017-11-21 2018-11-19 Sulfone pyridine alkyl amide-substituted heteroaryl compounds

Publications (1)

Publication Number Publication Date
MY202167A true MY202167A (en) 2024-04-12

Family

ID=65036887

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020002150A MY202167A (en) 2017-11-21 2018-11-19 Sulfone pyridine alkyl amide-substituted heteroaryl compounds

Country Status (20)

Country Link
US (4) US11021462B2 (https=)
EP (1) EP3713930A1 (https=)
JP (2) JP7258903B2 (https=)
KR (1) KR102702228B1 (https=)
CN (1) CN111315737B (https=)
AR (1) AR113895A1 (https=)
AU (3) AU2018371010C1 (https=)
BR (1) BR112020009606A2 (https=)
CA (1) CA3083122A1 (https=)
CL (1) CL2020001338A1 (https=)
CO (1) CO2020006139A2 (https=)
EA (1) EA202091269A1 (https=)
IL (1) IL274816B2 (https=)
MX (1) MX2020005210A (https=)
MY (1) MY202167A (https=)
PE (1) PE20211461A1 (https=)
SG (1) SG11202004592TA (https=)
TW (1) TWI776994B (https=)
WO (1) WO2019103952A1 (https=)
ZA (1) ZA202003717B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091269A1 (ru) * 2017-11-21 2020-08-07 Бристол-Маерс Сквибб Компани Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US12428395B2 (en) 2019-08-01 2025-09-30 Sperogenix Therapeutics Limited Heterocyclic compounds as kinase inhibitor and uses thereof
US12492184B2 (en) * 2020-12-22 2025-12-09 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CN114805438A (zh) * 2021-01-18 2022-07-29 正大天晴药业集团股份有限公司 含磷酰基的tyk2抑制剂化合物
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
CA3213816A1 (en) 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP2024512497A (ja) * 2021-03-17 2024-03-19 武田薬品工業株式会社 血漿カリクレインの阻害剤
WO2022206705A1 (zh) * 2021-03-30 2022-10-06 浙江文达医药科技有限公司 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
KR20240008337A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
CN115466289A (zh) * 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
AU2022412835A1 (en) 2021-12-16 2024-06-20 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN120661462A (zh) * 2022-06-20 2025-09-19 益方生物科技(上海)股份有限公司 药物组合物及其用途
CN117263913A (zh) * 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
WO2024125651A1 (zh) * 2022-12-16 2024-06-20 津药生物科技(天津)有限公司 新型含杂环取代的丙烯酸衍生物及其用途
WO2024217515A1 (zh) 2023-04-19 2024-10-24 上海复宏汉霖生物技术股份有限公司 一种杂环取代的芳香化合物、其制备方法及用途
AU2024325442A1 (en) 2023-08-14 2026-03-26 Shanghai Henlius Biologics Co., Ltd. Sulfonamide compound, and preparation method therefor and use thereof
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
WO2014060371A1 (en) 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibitors of syk
KR102233252B1 (ko) * 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 IL-12, IL-23 및/또는 IFNα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
US9382246B2 (en) 2013-12-05 2016-07-05 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
AR110351A1 (es) 2016-12-13 2019-03-20 Bristol Myers Squibb Co COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EA202091269A1 (ru) * 2017-11-21 2020-08-07 Бристол-Маерс Сквибб Компани Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения

Also Published As

Publication number Publication date
CN111315737A (zh) 2020-06-19
AU2022228101B2 (en) 2023-08-03
KR102702228B1 (ko) 2024-09-02
AU2023255024B2 (en) 2025-05-01
JP7258903B2 (ja) 2023-04-17
ZA202003717B (en) 2022-01-26
JP2023098942A (ja) 2023-07-11
CL2020001338A1 (es) 2020-09-25
WO2019103952A1 (en) 2019-05-31
AU2018371010A1 (en) 2020-07-02
PE20211461A1 (es) 2021-08-05
SG11202004592TA (en) 2020-06-29
US20190152948A1 (en) 2019-05-23
CO2020006139A2 (es) 2020-05-29
US20240002364A1 (en) 2024-01-04
EA202091269A1 (ru) 2020-08-07
NZ765438A (en) 2024-11-29
IL274816B2 (en) 2023-12-01
MX2020005210A (es) 2020-08-20
CA3083122A1 (en) 2019-05-31
JP2021504443A (ja) 2021-02-15
BR112020009606A2 (pt) 2020-11-03
US11787779B2 (en) 2023-10-17
US20250304555A1 (en) 2025-10-02
AU2018371010C1 (en) 2024-09-26
CN111315737B (zh) 2024-06-18
JP7490107B2 (ja) 2024-05-24
AU2022228101A1 (en) 2022-09-29
EP3713930A1 (en) 2020-09-30
AR113895A1 (es) 2020-06-24
IL274816B1 (en) 2023-08-01
US20210253554A1 (en) 2021-08-19
TWI776994B (zh) 2022-09-11
US11021462B2 (en) 2021-06-01
US12365667B2 (en) 2025-07-22
AU2023255024A1 (en) 2023-11-16
IL274816A (en) 2020-07-30
KR20200089706A (ko) 2020-07-27
AU2018371010B2 (en) 2022-06-09
TW201925187A (zh) 2019-07-01

Similar Documents

Publication Publication Date Title
MY202167A (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
MY198262A (en) AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNa RESPONSES
PH12016500779A1 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
MX2021004562A (es) Compuestos heterociclicos sustituidos con amida para el tratamiento de condiciones relacionadas con la modulacion de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifn-alfa).
MX2021008752A (es) Compuestos de piridina o piridazina disustituidos con amida.
MX2020009347A (es) Picolinamidas como fungicidas.
JOP20180011A1 (ar) مشتقات بيرولو [1، 2-b]بيريدازين
EA201590913A1 (ru) АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
TN2015000175A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
EA201790722A1 (ru) КОМПОЗИЦИЯ С НИЗКИМ pH, СОДЕРЖАЩАЯ КОНКРЕТНЫЕ КОНСЕРВАЦИОННЫЕ СИСТЕМЫ
EA201590911A1 (ru) АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
TN2016000567A1 (en) Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
MX2020010657A (es) Derivados de oxadiazolina.
EA201892449A1 (ru) Конденсированные гетероциклические соединения
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
MX2021015514A (es) Compuesto heterociclico.
MX2021003481A (es) Compuesto heterociclico.
MY177032A (en) Aqueous composition
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
MX2019015747A (es) Compuesto heterociclico.
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
NZ742115A (en) Novel citric acid derivative
MX2018005198A (es) Metodo para sintetizar acidos 2-alquil-4-trifluorometil-3-alquilsu lfonilbenzoicos.
MX2018011117A (es) Forma cristalina.